Recombinant growth hormone therapy in children with Turner Syndrome in Korea: a phase III Randomized Trial.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

Short stature is the most consistent characteristic feature of Turner syndrome (TS).

The study was registered at ClinicalTrials.gov.

Who Took Part

By PubMed's age tags, the people studied were young children and children, women only.

How the Study Was Run

The design is described as randomized, open-label and parallel-group.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Everyone knew when Exogenous HGH, sermorelin & older GHRPs (why they're passed over) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Groups ran in parallel: each of the participants stayed in one arm throughout.

This open-label, active-controlled, parallel-group, randomized controlled phase III trial was conducted at 11 hospitals in Korea.

What Was Measured

The subject headings attached to it are Body Height, Growth Hormone, Hormone Replacement Therapy, Recombinant Proteins, Republic of Korea and Turner Syndrome.

The authors tagged it with the keywords Short stature.

What This Means in Plain Language

The paper is a randomized, open-label and parallel-group study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2021 (BMC endocrine disorders), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.